Scabies Itch - 19/06/18

Doi : 10.1016/j.det.2018.02.009

Arnaud Jannic, MD ^a,^b,^⁎ , Charlotte Bernigaud, MD ^a,^b, Emilie Brenaut, MD ^c,^d, Olivier Chosidow, MD, PhD ^a,^e
^a Dermatology Department, AP-HP, Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France
^b Research Group Dynamyc, Ecole nationale vé té rinaire d'Alfort, Maisons-Alfort, Université Paris-Est Créteil, EA7380, Créteil, France
^c Dermatology Department, University hospital of Brest, 2 avenue Foch, 29200, Brest, France
^d Laboratory on Interactions Neurons-Keratinocytes (LINK), University of Western Brittany, EA4685, 29238 Brest, France
^e EpiDermE, Epidé miologie en Dermatologie et Evaluation des Thé rapeutiques, Université Paris-Est Créteil, EA 7379, 9400 Créteil, France

^∗Corresponding author. Dermatology Department, AP-HP, Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France.Dermatology Department, AP-HPHôpital Henri Mondor51 avenue du Maréchal de Lattre de TassignyCréteil94010France

Résumé

Itch is the cardinal symptom of scabies, present in more than 90% of the cases, generalized and intense, worsening at night, and often sparing the head. The primary complications of the itch in scabies are secondary bacterial infections and psychosocial issues leading to impairment on life quality. Currently, there are no specific data analyzing mechanisms of the itch in scabies, but the latest progress made in the understanding of host-mite interactions may help to improve understanding. Management of itch in scabies consists primarily of the treatment of the mite infestation, but sometimes the itching sensation may persist after adequate therapy.

Le texte complet de cet article est disponible en PDF.

Keywords : Itch, Pruritus, Scabies, Sarcoptes scabiei

Plan

Key points

What is scabies?

Scabies itch: clinical aspects

Characteristics

Prevalence

Complications of Itch in scabies

Causes of Persistent Itch After Treatment

Summary

Disclosure Statement: C. Bernigaud reports receiving a research grant from MSD France; a research support from Bioderma Laboratoire Dermatologique and Codexial Dermatologie; and a travel grant from Medicines Development. O. Chosidow reports receiving drugs donated free of charge for research from Codexial Dermatologie and MSD France, lecture fees from Zambon Laboratoire, Codexial Dermatologie, and MSD France. No other potential conflict of interest was reported.